Exploration of the MSI landscape in Chinese pan-cancer patient by Next-Generation Sequencing.

Authors

null

Xinlu Liu

Department of Anorectal Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China

Xinlu Liu , Jiasheng Xu , Jian Sun , Deng Wei , Xinsheng Zhang , Danhua Wang , Tonghui Ma

Organizations

Department of Anorectal Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China, Genetron Health (Beijing) Co. Ltd., Hangzhou, China, Department of Thoracic Surgery, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China, Department of General Surgery, Medical Oncology Group; Beijing Friendship Hospital, Capital Medical University, Beijing, China, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, China, Genetron Health (Beijing) Technology, Co., Ltd., Beijing, China

Research Funding

Pharmaceutical/Biotech Company
genetronhealth

Background: Clinically, MSI had been used as an important molecular marker for the prognosis of colorectal cancer and other solid tumors and the formulation of adjuvant treatment plans, and it had been used to assist in the screening of Lynch syndrome. However, there were currently few reports on the incidence of MSI-H in Chinese pan-cancer patients. This study described the occurrence of MSI in a large multi-center pan-cancer cohort in China, and explored the correlation between MSI and patients' TMB, age, PD-L1 expression and other indicators. Methods: The study included 8361 patients with 8 cancer types from multiple tumor centers. Use immunohistochemistry to detect the expression of MMR protein (MLH1, MSH2, MSH6 and PMS2) in patients with various cancer types to determine the MSI status and detect the expression of PD-L1 in patients. Through NGS technology, 831 genes of 8361 Chinese cancer patients were sequenced and the tumor mutation load of the patients was calculated. The MSI mutations of patients in 8 cancer types were analyzed and the correlation between MSI mutations of patients and the patient's age, TMB and PD-L1 expression was analyzed. Results: The test results showed that MSI patients accounted for 1.66% of pan-cancers. Among them, MSI-H patients accounted for the highest proportion in intestinal cancer, reaching 7.2%. The correlation analysis between MSI and TMB was performed on patients of various cancer types. The results showed that: in each cancer type, MSI-H patients had TMB greater than 10, and 26.83% of MSI-H patients had TMB greater than 100 in colorectal cancer patients. The result of correlation analysis showed that there was no significant correlation between the patient's age and the risk of MSI mutation (P> 0.05). In addition to PAAD and LUAD, the expression of PD-L1 in MSI-H patients was higher than that in MSS patients in other cancer types(P< 0.05). The correlation analysis between PD-L1 expression and TMB in patients found that in colorectal cancer, the higher the expression of PD-L1, the higher the patient's TMB (P< 0.05). Conclusions: In this study, we explored the incidence of MSI-H in pan-cancer patients in China and found that the TMB was greater than 10 in patients with MSI-H. Compared with MSS patients, MSI-H patients have higher PD-L1 expression, and the higher the PD-L1 expression in colorectal cancer, the higher the TMB value of patients.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other IO-Related Topics

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr e14576)

DOI

10.1200/JCO.2021.39.15_suppl.e14576

Abstract #

e14576

Abstract Disclosures